A phase i study of light dose for photodynamic therapy using 2-[1-Hexyloxyethyl]-2 devinyl pyropheophorbide-A for the treatment of non-small cell carcinoma in situ or non-small cell microinvasive bronchogenic carcinoma: A dose ranging study

Journal of Thoracic Oncology

Volumn 11, Issue 2, 2016, Pages 234-241

  Dhillon, Samjot Singh ^a   Demmy, Todd L ^b   Yendamuri, Sai ^a   Loewen, Gregory ^c   Nwogu, Chukwumere ^a   Cooper, Michele ^c   Henderson, Barbara W ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Bronchoscopy; Carcinoma in situ; Lung cancer; Photodynamic therapy

Indexed keywords

2 [1 HEXYLOXYETHYL] 2 DEVINYL PYROPHEOPHORBIDE A; PHOTOFRIN; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG; 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A; CHLOROPHYLL;

ADULT; AGED; ARTICLE; BRONCHOSCOPY; CARCINOMA IN SITU; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COUGHING; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; ERYTHEMA; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LUNG CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; NON SMALL CELL CARCINOMA IN SITU; NON SMALL CELL LUNG CANCER; NON SMALL CELL MICROINVASIVE BRONCHOGENIC CARCINOMA; PAIN; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOPHOBIA; PHOTOTOXICITY; PNEUMOTHORAX; PRIORITY JOURNAL; RADIATION DOSE; RESPIRATORY DISTRESS; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CARCINOMA, BRONCHOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DOSE RESPONSE; LUNG NEOPLASMS; MIDDLE AGED; PHOTOCHEMOTHERAPY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, BRONCHOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CHLOROPHYLL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 84958953454     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.10.020     Document Type: Article

References (32)

1. Dhillon SS, Loewen G, Jayaprakash V, Reid ME. Lung cancer screening update. J Carcinog. 2013;12:2.
2. Daniels JM, Sutedja TG. Detection and minimally invasive treatment of early squamous lung cancer. Ther Adv Med Oncol. 2013;5:235-248.
3. Simone 2nd CB, Friedberg JS, Glatstein E, et al. Photodynamic therapy for the treatment of non-small cell lung cancer. J Thorac Dis. 2012;4:63-75.
4. Corti L, Toniolo L, Boso C, et al. Long-Term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers Surg Med. 2007;39:394-402.
5. Ikeda N, Usuda J, Kato H, et al. New aspects of photodynamic therapy for central type early stage lung cancer. Lasers Surg Med. 2011;43:749-754.
6. Furuse K, Fukuoka M, Kato H, et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol. 1993;11:1852-1857.
7. Loewen GM, Pandey R, Bellnier D, et al. Endobronchial photodynamic therapy for lung cancer. Lasers Surg Med. 2006;38:364-370.
8. Moghissi K, Dixon K. Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer? Eur Respir J. 2003;22:535-541.
9. Usuda J, Kato H, Okunaka T, et al. Photodynamic therapy (PDT) for lung cancers. J Thorac Oncol. 2006;1:489-493.
10. Usuda J, Tsutsui H, Honda H, et al. Photodynamic therapy for lung cancers based on novel photodynamic diagnosis using talaporfin sodium (NPe6) and autofluorescence bronchoscopy. Lung Cancer. 2007;58:317-323.
11. Kato H, Furukawa K, Sato M, et al. Phase II clinical study of photodynamic therapy using mono-L-Aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer. 2003;42:103-111.
12. Bellnier DA, Greco WR, Nava H, et al. Mild skin photosensitivity in cancer patients following injection of Photochlor (2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-A; HPPH) for photodynamic therapy. Cancer Chemother Pharmacol. 2006;57:40-45.
13. Nava HR, Allamaneni SS, Dougherty TJ, et al. Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barretts esophagus. Lasers Surg Med. 2011;43:705-712.
14. Rigual N, Shafirstein G, Cooper MT, et al. Photodynamic therapy with 3-(10-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity. Clin Cancer Res. 2013;19:6605-6613.
15. Shafirstein G, Rigual NR, Arshad H, et al. Photodynamic therapy with 3-(10-hexyloxyethyl) pyropheophorbide a (HPPH) for early stage cancer of the larynx: phase Ib study [Epub ahead of print]. Head Neck. http://dx.doi.org/10.1002/hed.24003, accessed May 6, 2015.
16. Lin Y, Shih WJ. Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics. 2001;2:203-215.
17. Loewen G, Reid M, Tan D, et al. Bimodality lung cancer screening in high-risk patients: A preliminary report. Chest. 2004;125(suppl):163S-164S.
18. Loewen G, Natarajan N, Tan D, et al. Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment. Thorax. 2007;62:335-340.
19. Jayaprakash V, Loewen GM, Dhillon SS, et al. Early detection of lung cancer using CT scan and bronchoscopy in a high risk population. J Cancer Ther. 2012;3:388-396.
20. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest. 1998;113:696-702.
21. National Cancer Institute website. Common terminology criteria for adverse events (CTCAE). Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed May 6, 2015.
22. Kato H, Usuda J, Okunaka T, et al. Basic and clinical research on photodynamic therapy at Tokyo Medical University Hospital. Lasers Surg Med. 2006;38:371-375.
23. Usuda J, Ichinose S, Ishizumi T, et al. Outcome of photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways 1.0 cm in diameter. Clin Cancer Res. 2010;16:2198-2204.
24. Simone 2nd CB, Cengel KA. Photodynamic therapy for lung cancer and malignant pleural mesothelioma. Semin Oncol. 2014;41:820-830.
25. Usuda J, Ichinose S, Ishizumi T, et al. Management of multiple primary lung cancer in patients with centrally located early cancer lesions. J Thorac Oncol. 2010;5: 62-68.
26. Bellnier DA, Greco WR, Loewen GM, et al. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-A in cancer patients. Cancer Res. 2003;63:1806-1813.
27. Tracy EC, Bowman MJ, Pandey RK, et al. Cell-Type selective phototoxicity achieved with chlorophyll-A derived photosensitizers in a co-culture system of primary human tumor and normal lung cells. Photochem Photobiol. 2011;87:1405-1418.
28. Edell E, Lam S, Pass H, et al. Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: An international, multicenter clinical trial. J Thorac Oncol. 2009;4:49-54.
29. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294-299.
30. Endo C, Miyamoto A, Sakurada A, et al. Results of long-Term follow-up of photodynamic therapy for roentgenographically occult bronchogenic squamous cell carcinoma. Chest. 2009;136:369-375.
31. Kurimoto N, Murayama M, Yoshioka S, et al. Assessment of usefulness of endobronchial ultrasonography in determination of depth of tracheobronchial tumor invasion. Chest. 1999;115:1500-1506.
32. Takahashi H, Sagawa M, Sato M, et al. A prospective evaluation of transbronchial ultrasonography for assessment of depth of invasion in early bronchogenic squamous cell carcinoma. Lung Cancer. 2003;42:43-49.